BR112019001528A8 - new cannabus tablet formulations and compositions and production methods - Google Patents
new cannabus tablet formulations and compositions and production methodsInfo
- Publication number
- BR112019001528A8 BR112019001528A8 BR112019001528A BR112019001528A BR112019001528A8 BR 112019001528 A8 BR112019001528 A8 BR 112019001528A8 BR 112019001528 A BR112019001528 A BR 112019001528A BR 112019001528 A BR112019001528 A BR 112019001528A BR 112019001528 A8 BR112019001528 A8 BR 112019001528A8
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cannabus
- new
- production methods
- tablet formulations
- Prior art date
Links
- 239000007916 tablet composition Substances 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 229930003827 cannabinoid Natural products 0.000 abstract 2
- 239000003557 cannabinoid Substances 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
são aqui divulgadas composições compreendendo um óleo tendo pelo menos um canabinóide e pelo menos um pó sólido e métodos para fabricar e usar o mesmo. numa modalidade, as composições aqui divulgadas são adequadas para preparar comprimidos contendo canabinóides pressionando uma composição desta divulgação com um ou mais agentes de formulação, tais como aglutinantes, enchimentos, agentes de volume, excipientes, etc.Disclosed herein are compositions comprising an oil having at least one cannabinoid and at least one solid powder and methods for making and using it. In one embodiment, the compositions disclosed herein are suitable for preparing cannabinoid-containing tablets by pressing a composition of this disclosure with one or more formulating agents, such as binders, fillers, bulking agents, excipients, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662366517P | 2016-07-25 | 2016-07-25 | |
PCT/US2017/043808 WO2018022669A1 (en) | 2016-07-25 | 2017-07-25 | New cannabis tablet formulations and compositions and methods of making the same |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112019001528A2 BR112019001528A2 (en) | 2019-06-18 |
BR112019001528A8 true BR112019001528A8 (en) | 2019-07-09 |
Family
ID=61017335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001528A BR112019001528A8 (en) | 2016-07-25 | 2017-07-25 | new cannabus tablet formulations and compositions and production methods |
Country Status (12)
Country | Link |
---|---|
US (3) | US20190183850A1 (en) |
EP (1) | EP3487482A4 (en) |
CN (1) | CN109789095A (en) |
AU (1) | AU2017302559A1 (en) |
BR (1) | BR112019001528A8 (en) |
CA (1) | CA3031533A1 (en) |
CL (1) | CL2019000198A1 (en) |
CO (1) | CO2019000787A2 (en) |
IL (1) | IL264386B2 (en) |
MX (1) | MX2019001121A (en) |
PE (1) | PE20200478A1 (en) |
WO (1) | WO2018022669A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3755309A1 (en) * | 2018-02-23 | 2020-12-30 | Columbia Care LLC | Hard-pressed scored splittable marijuana tablets |
WO2019211772A1 (en) * | 2018-05-03 | 2019-11-07 | Radient Technologies Inc. | Obtaining extracts in a solid form |
WO2020092352A1 (en) * | 2018-10-30 | 2020-05-07 | Kelsie Biotech, Llc | Tablets, formulations and methods for low melting point active ingredients |
US20220023220A1 (en) * | 2019-01-10 | 2022-01-27 | Columbia Care Llc | Rapidly disintegrating oral tablet |
CA3040547C (en) | 2019-04-17 | 2021-12-07 | Medcan Pharma A/S | Cannabinoid lozenge formulation |
US11633351B2 (en) | 2019-12-13 | 2023-04-25 | Nordiccan A/S | Fast disintegrating cannabinoid tablets |
US10925853B2 (en) | 2019-04-17 | 2021-02-23 | Nordiccan A/S | Oral cannabinoid tablet |
US20230065736A1 (en) * | 2020-01-08 | 2023-03-02 | Société des Produits Nestlé S.A. | Oral solid cannabinoid oil composition for treating gastrointestinal disorders |
CA3219553A1 (en) * | 2021-05-21 | 2022-11-24 | Rama JUDE | Process for incorporating additives into aerosol-producing substrates and products made therefrom |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7908791A (en) * | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
AU5719798A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
WO2002064109A2 (en) * | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
PA8576201A1 (en) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO |
WO2008033023A2 (en) * | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture |
CN101810593B (en) * | 2010-05-10 | 2012-07-18 | 谢恬 | Elemene sustained-release tablets |
CA2992923C (en) * | 2014-07-21 | 2021-06-29 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal and sublingual administration of cannabinoids |
US20180303791A1 (en) * | 2014-11-26 | 2018-10-25 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
US10172786B2 (en) * | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
-
2017
- 2017-07-25 WO PCT/US2017/043808 patent/WO2018022669A1/en unknown
- 2017-07-25 US US16/320,557 patent/US20190183850A1/en not_active Abandoned
- 2017-07-25 BR BR112019001528A patent/BR112019001528A8/en not_active Application Discontinuation
- 2017-07-25 CA CA3031533A patent/CA3031533A1/en active Pending
- 2017-07-25 AU AU2017302559A patent/AU2017302559A1/en not_active Abandoned
- 2017-07-25 MX MX2019001121A patent/MX2019001121A/en unknown
- 2017-07-25 CN CN201780058464.XA patent/CN109789095A/en active Pending
- 2017-07-25 PE PE2019000259A patent/PE20200478A1/en unknown
- 2017-07-25 EP EP17835148.2A patent/EP3487482A4/en active Pending
-
2019
- 2019-01-21 IL IL264386A patent/IL264386B2/en unknown
- 2019-01-25 CL CL2019000198A patent/CL2019000198A1/en unknown
- 2019-01-28 CO CONC2019/0000787A patent/CO2019000787A2/en unknown
-
2020
- 2020-12-16 US US17/123,866 patent/US20210100771A1/en not_active Abandoned
-
2022
- 2022-06-15 US US17/841,456 patent/US20220323403A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019001528A2 (en) | 2019-06-18 |
IL264386A (en) | 2019-02-28 |
CL2019000198A1 (en) | 2019-05-31 |
CN109789095A (en) | 2019-05-21 |
EP3487482A4 (en) | 2020-03-04 |
CO2019000787A2 (en) | 2019-04-30 |
IL264386B2 (en) | 2023-08-01 |
PE20200478A1 (en) | 2020-03-03 |
US20220323403A1 (en) | 2022-10-13 |
WO2018022669A1 (en) | 2018-02-01 |
CA3031533A1 (en) | 2018-02-01 |
MX2019001121A (en) | 2019-10-21 |
US20190183850A1 (en) | 2019-06-20 |
IL264386B1 (en) | 2023-04-01 |
AU2017302559A1 (en) | 2019-02-07 |
US20210100771A1 (en) | 2021-04-08 |
EP3487482A1 (en) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001528A2 (en) | new cannabus tablet formulations and compositions and production methods | |
BR112017018276A2 (en) | ? composition comprising peptidase and biotensive agent and their use? | |
MX2018006217A (en) | Apelin receptor agonists and methods of use. | |
BR112018008877A2 (en) | ret inhibitors | |
MX2018014154A (en) | Modulatory polynucleotides. | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
MX2022015755A (en) | Pth prodrugs. | |
MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
BR112019002371A2 (en) | pharmaceutical compositions | |
EA201900562A1 (en) | BIS-OCTAGHYDROPHENANTHRENE CARBOXAMIDES AND THEIR PROTEIN CONJUGATES | |
NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
MX2020011478A (en) | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)- 1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses. | |
BR112018013985A2 (en) | highly soluble steviol glycosides | |
TR201821116A2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD | |
MX2020002123A (en) | Ribociclib salts and solid state forms thereof. | |
BR112018006730A2 (en) | method for preparing a compound, substance or mixture of substance, use of at least one substance or mixture of substance, fragrance composition, and, agent. | |
BR112016029765A2 (en) | ethylene-based polymers comprising carbon monoxide-derived units and a rheology modifying agent | |
MX367669B (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses. | |
MX2020008125A (en) | Compositions comprising berberine. | |
BR112018071370A2 (en) | mesalazine oral pharmaceutical compositions | |
WO2020131586A3 (en) | Methods for identifying neoantigens | |
MX2019005855A (en) | Powderous formulations. | |
MX2018002416A (en) | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the prodcution and use thereof. | |
BR112019002545A2 (en) | lactobacillus salivarius, composition for animal feed additives, animal feed and method for preparing lactobacillus salivarius | |
BR112018076287A2 (en) | methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity and refractory celiac disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |